Investment Trends in Early Stage BioPharma Report
This report covers:
- The total funding raised for Series A rounds in the last 6 years.
Trends in upfront licensing payments illustrating the continued faith in biologicals over advanced therapeutics. - The fluctuations in market activity, with Q1 2024 marking a significant resurgence in biopharma IPOs despite a quieter start in terms of overall deal numbers compared to the previous year.
- Additionally, we present a comparative study of the number and types of deals in Q1 2023 versus Q1 2024, offering a snapshot of the evolving investment landscape.
- Stay ahead of the curve and enhance your investment strategy with insights from our comprehensive report.
You May Also Be Interested In…
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
